ADC Therapeutics (ADCT) Non Operating Interest Expenses (2020 - 2026)
ADC Therapeutics' (ADCT) quarterly Non Operating Interest Expenses came in at $13.5 million in Q2 2026, up 3.93% year-over-year from $13.0 million in Q2 2025, and up 9.39% quarter-over-quarter from $12.3 million in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Non Operating Interest Expenses across 7 years of filings, most recently posting $13.5 million for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | ADC Therapeutics | 188.34 Mn | -30.76 Mn | 17.14 Mn | 13.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.51 Mn |
| Mar 31, 2026 | 12.35 Mn |
| Sep 30, 2025 | 13.39 Mn |
| Jun 30, 2025 | 13.00 Mn |
| Mar 31, 2025 | 12.23 Mn |
| Sep 30, 2024 | 13.12 Mn |
| Jun 30, 2024 | 12.68 Mn |
| Mar 31, 2024 | 12.50 Mn |
| Sep 30, 2023 | 12.82 Mn |
| Jun 30, 2023 | 10.31 Mn |
| Mar 31, 2023 | 10.42 Mn |
| Sep 30, 2022 | 11.36 Mn |
| Jun 30, 2022 | 8.80 Mn |
| Mar 31, 2022 | 9.22 Mn |
| Sep 30, 2021 | 4.27 Mn |
| Jun 30, 2021 | 2.56 Mn |
| Mar 31, 2021 | 2.00 Mn |
| Sep 30, 2020 | 1.94 Mn |
| Jun 30, 2020 | 897,000.00 |
| Mar 31, 2020 | 42,000.00 |